Sanpower seals groundbreaking medical deal

Conglomerate boosts China's push to revolutionise its health sector by buying US biotech pioneer Dendreon. It complements Sanpower's previous investment in more prosaic health assets.

A vacuum in quality healthcare has emerged as a key challenge for the world's most populous nation, as policymakers wrestle with problems including a shortage of skilled professionals, slow drug clearance procedures and services that are unaffordable to most ordinary Chinese.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media